Recent advancements in oncology and immunology have led to the development of biologics, which are newer drugs that target specific molecules involved in tumorigenesis and inflammatory pathways. The current use of targeted therapy has transformed the therapeutic approach for many orbital cancers and inflammatory disorders that were previously treated with conventional treatment modalities. The purpose of this article is to highlight the therapeutic potential of targeted therapy for common orbital cancers and inflammatory conditions.